PDS BiotechnologyPDSB
PDSB
About: PDS Biotechnology Corp operates as a clinical stage biotechnology company, principally involved in drug discovery in the United States. It is engaged in the treatment of various early-stage and late-stage cancers, including head and neck cancer, prostate cancer, breast cancer, cervical cancer, anal cancer, and other cancers. Its products are based on the proprietary Versamune platform technology, which activates and directs the human immune system to unleash a powerful and targeted attack against cancer cells.
Employees: 24
0
Funds holding %
of 7,312 funds
–
Analysts bullish %
Fund manager confidence
Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)
15,650% more call options, than puts
Call options by funds: $315K | Put options by funds: $2K
42% more capital invested
Capital invested by funds: $6.91M [Q4 2024] → $9.79M (+$2.87M) [Q1 2025]
6.79% more ownership
Funds ownership: 11.33% [Q4 2024] → 18.12% (+6.79%) [Q1 2025]
8% less repeat investments, than reductions
Existing positions increased: 11 | Existing positions reduced: 12
8% less funds holding
Funds holding: 51 [Q4 2024] → 47 (-4) [Q1 2025]
25% less first-time investments, than exits
New positions opened: 9 | Existing positions closed: 12
Research analyst outlook
1 Wall Street Analyst provided 1 year price targets over the past 3 months
Low target
$13
948%
upside
Avg. target
$13
948%
upside
High target
$13
948%
upside
1 analyst rating
1 positive
100%
0 neutral
0%
0 negative
0%
HC Wainwright & Co. Joseph Pantginis | 948%upside $13 | Buy Reiterated | 1 Jul 2025 |
Financial journalist opinion
Neutral
GlobeNewsWire
1 day ago
PDS Biotech Announces Colorectal Cancer Cohort of Phase 2 Clinical Trial with PDS01ADC Met Criteria for Expansion to Stage 2 Following Positive Stage 1 Results
PRINCETON, N.J., July 10, 2025 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB) (“PDS Biotech” or the “Company”), a late-stage immunotherapy company focused on transforming how the immune system targets and kills cancers, today announced patient recruitment has been completed in Stage 1 of a clinical trial of the Company's PDS01ADC therapeutic administered systemically in combination with floxuridine (FUDR) administered by hepatic artery infusion pump (HAIP) for patients with metastatic colorectal cancer (NCT05286814), led by the National Cancer Institute (NCI), a component of the National Institutes of Health (NIH).
Neutral
GlobeNewsWire
1 month ago
PDS Biotech to Host Key Opinion Leader Event to Discuss Versamune® HPV for the Treatment of HPV16+ HNSCC
Event to Discuss the Changing Landscape of HNSCC in context with the Merck KN-689 study and the Rapidly Increasing Incidences of HPV16-positive HNSCC in the United States and Europe
Neutral
GlobeNewsWire
1 month ago
PDS Biotech Unveils Updated Positive Data From VERSATILE-002 Trial and Additional Trials Evaluating Versamune® HPV to Treat Head and Neck Cancers at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting
PDS Biotech announced the publication of three Versamune® HPV abstracts that were presented during the Head and Neck Cancer Poster Session at ASCO 2025.
Neutral
GlobeNewsWire
1 month ago
PDS Biotech Announces Positive Extended Follow-Up Data for VERSATILE-002 and Additional Trials Evaluating Versamune® HPV to be Presented at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting
Phase 2: Versamune ® HPV with pembrolizumab as 1L treatment of r/m HPV16-positive HNSCC
Neutral
GlobeNewsWire
1 month ago
PDS Biotech to Participate at the A.G.P. Virtual Annual Healthcare Company Showcase
PRINCETON, N.J., May 20, 2025 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB) (“PDS Biotech” or the “Company”), a late-stage immunotherapy company focused on transforming how the immune system targets and kills cancers, today announced that Frank Bedu-Addo, PhD, President and Chief Executive Officer of PDS Biotech will participate in a fireside chat during the Alliance Global Partners (“A.G.P.”) Virtual Annual Healthcare Company Showcase, taking place May 21, 2025.
Positive
Proactive Investors
1 month ago
EMV Capital portfolio company PDS Biotech advances cancer trial
PDS Biotechnology Corporation (NASDAQ:PDSB), a US cancer immunotherapy firm backed by EMV Capital (AIM:EMVC), has begun site activations for its phase III trial of Versamune HPV in patients with head and neck cancers linked to HPV16. The trial, which will enrol around 350 patients, is supported by the US Food and Drug Administration Fast Track designation and includes interim data readouts.
Neutral
Seeking Alpha
1 month ago
PDS Biotechnology Corporation (PDSB) Q1 2025 Earnings Call Transcript
PDS Biotechnology Corporation (NASDAQ:PDSB ) Q1 2025 Earnings Conference Call May 14, 2025 8:30 AM ET Company Participants Frank Bedu-Addo - CEO Lars Boesgaard - CFO Kirk Shepard - Chief Medical Officer Mike Moyer - IR, LifeSci Advisors Conference Call Participants Mayank Mamtani - B. Riley Securities Joseph Pantginis - H.C.
Neutral
GlobeNewsWire
1 month ago
PDS Biotech Reports First Quarter 2025 Financial Results and Provides Clinical Programs and Corporate Update
VERSATILE-003 Phase 3 Site Initiations Underway Multiple Abstracts Selected for Presentation at the 2025 American Society of Clinical Oncology Annual Meeting Conference call and webcast today at 8:00 a.m. Eastern Time PRINCETON, N.J.
Neutral
GlobeNewsWire
2 months ago
PDS Biotechnology Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
PRINCETON, N.J., May 09, 2025 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB) (“PDS Biotech” or the “Company”), a late-stage immunotherapy company focused on transforming how the immune system targets and kills cancers, today announced that on May 5, 2025, PDS Biotech granted a nonstatutory stock option to purchase 5,000 shares of common stock to an employee in its clinical department as a material inducement to such employee's employment and in accordance with Nasdaq Listing Rule 5635(c)(4) and PDS Biotech's 2019 Inducement Plan, as amended, which was adopted on June 17, 2019, and provides for the granting of equity awards to new employees of PDS Biotech.
Neutral
GlobeNewsWire
2 months ago
PDS Biotech Announces Additional Details on Two Preclinical Universal Influenza Presentations at IMMUNOLOGY2025™ Annual Meeting
PRINCETON, N.J., May 08, 2025 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB) (“PDS Biotech” or the “Company”), a late-stage immunotherapy company focused on transforming how the immune system targets and kills cancers and infectious diseases, today provided updates on preclinical immune response data with a novel, investigational Infectimune® based flu vaccine that were featured at the American Association of Immunologists' IMMUNOLOGY2025™ Annual Meeting, which took place May 3-7, 2025, in Honolulu, Hawaii.
Charts implemented using Lightweight Charts™